Post-operative Cataract Surgery Inflammation Market Growth Projections 2024-2034: DelveInsight Analysis | Mallinckrodt Pharma, Salix Pharma, GlaxoSmithKline, Pfizer Inc.

DelveInsight's "Post-operative Cataract Surgery Inflammation Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Post-operative Cataract Surgery Inflammation, historical and forecasted epidemiology as well as the Post-operative Cataract Surgery Inflammation market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post-operative Cataract Surgery Inflammation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-operative Cataract Surgery Inflammation Market Forecast
https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Post-operative Cataract Surgery Inflammation Market Report:
• The Post-operative Cataract Surgery Inflammation market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2024, VivaVision Biotech, a clinical-stage, privately owned biotechnology company dedicated to developing therapies for ocular diseases, today revealed positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201. This potent non-steroidal dual JAK1/TYK2 immunomodulator is being developed to treat post-operative inflammation following cataract surgery.
• In December 2024, VivaVision Biotech, based in China, plans to move forward with its non-steroidal therapy, VVN461-CS-201 (VVN461), into a Phase III trial after the candidate successfully met the primary endpoint in a Phase II U.S. study focused on treating post-operative inflammation following cataract surgery.
• As per the National Eye Institute, cataracts affected 17.11% of the U.S. population in 2010. Additionally, over half of Americans aged 80 and above either have cataracts or have undergone surgery to remove them.
• According to the American Academy of Ophthalmology, over 24.4 million Americans aged 40 and above are affected by cataracts. By the age of 75, nearly half of the U.S. population has cataracts as of 2023.
• Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others
• Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 - Dexamethasone, Nepafenac Ophthalmic Suspension, and others
• The Post-operative Cataract Surgery Inflammation epidemiology based on gender analyzed that females were more affected by cataract than men
• The Post-operative Cataract Surgery Inflammation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-operative Cataract Surgery Inflammation pipeline products will significantly revolutionize the Post-operative Cataract Surgery Inflammation market dynamics.

Post-operative Cataract Surgery Inflammation Overview
A cataract is a clouded spot in the eye's lens, which is clear and helps to concentrate light. Cataracts are quite frequent in older people. In actuality, more than half of all Americans 80 years of age and older either have cataracts or have undergone cataract surgery. Additionally, it is the leading global cause of blindness.

Get a Free sample for the Post-operative Cataract Surgery Inflammation Market Report
https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post-operative Cataract Surgery Inflammation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post-operative Cataract Surgery Inflammation Epidemiology Segmentation:
The Post-operative Cataract Surgery Inflammation market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Post-operative Cataract Surgery Inflammation
• Prevalent Cases of Post-operative Cataract Surgery Inflammation by severity
• Gender-specific Prevalence of Post-operative Cataract Surgery Inflammation
• Diagnosed Cases of Episodic and Chronic Post-operative Cataract Surgery Inflammation

Download the report to understand which factors are driving Post-operative Cataract Surgery Inflammation epidemiology trends @ Post-operative Cataract Surgery Inflammation Epidemiology Forecast
https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post-operative Cataract Surgery Inflammation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-operative Cataract Surgery Inflammation market or expected to get launched during the study period. The analysis covers Post-operative Cataract Surgery Inflammation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post-operative Cataract Surgery Inflammation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-operative Cataract Surgery Inflammation Therapies and Key Companies
• OCS-01: Oculis
• APP13007: Formosa Pharmaceuticals/AimMaxTherapeutics
• SVT15473: Salvat Laboratories
• Ster: Azidus Brasil
• Bromfenac: Bausch & Lomb Incorporated
• Difluprednate: Laboratorios Poen
• OCS-01 - Dexamethasone: Oculis
• Nepafenac Ophthalmic Suspension: Alcon Research

Discover more about therapies set to grab major Post-operative Cataract Surgery Inflammation market share @ Post-operative Cataract Surgery Inflammation Treatment Market
https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post-operative Cataract Surgery Inflammation Market Strengths
• Advances in surgical techniques
• Advances in the understanding of ophthalmology
• Pipeline consists of late and early stage candidates.

Post-operative Cataract Surgery Inflammation Market Opportunities
• Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs
• The side effects associated with therapies currently give a window of opportunity to pharma payer to bring in novel therapies.

Scope of the Post-operative Cataract Surgery Inflammation Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others
• Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 - Dexamethasone, Nepafenac Ophthalmic Suspension, and others
• Post-operative Cataract Surgery Inflammation Therapeutic Assessment: Post-operative Cataract Surgery Inflammation current marketed and Post-operative Cataract Surgery Inflammation emerging therapies
• Post-operative Cataract Surgery Inflammation Market Dynamics: Post-operative Cataract Surgery Inflammation market drivers and Post-operative Cataract Surgery Inflammation market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Post-operative Cataract Surgery Inflammation Unmet Needs, KOL's views, Analyst's views, Post-operative Cataract Surgery Inflammation Market Access and Reimbursement

To know more about Post-operative Cataract Surgery Inflammation companies working in the treatment market, visit @ Post-operative Cataract Surgery Inflammation Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Post-operative Cataract Surgery Inflammation Market Report Introduction
2. Executive Summary for Post-operative Cataract Surgery Inflammation
3. SWOT analysis of Post-operative Cataract Surgery Inflammation
4. Post-operative Cataract Surgery Inflammation Patient Share (%) Overview at a Glance
5. Post-operative Cataract Surgery Inflammation Market Overview at a Glance
6. Post-operative Cataract Surgery Inflammation Disease Background and Overview
7. Post-operative Cataract Surgery Inflammation Epidemiology and Patient Population
8. Country-Specific Patient Population of Post-operative Cataract Surgery Inflammation
9. Post-operative Cataract Surgery Inflammation Current Treatment and Medical Practices
10. Post-operative Cataract Surgery Inflammation Unmet Needs
11. Post-operative Cataract Surgery Inflammation Emerging Therapies
12. Post-operative Cataract Surgery Inflammation Market Outlook
13. Country-Wise Post-operative Cataract Surgery Inflammation Market Analysis (2020-2034)
14. Post-operative Cataract Surgery Inflammation Market Access and Reimbursement of Therapies
15. Post-operative Cataract Surgery Inflammation Market Drivers
16. Post-operative Cataract Surgery Inflammation Market Barriers
17. Post-operative Cataract Surgery Inflammation Appendix
18. Post-operative Cataract Surgery Inflammation Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Post-operative Cataract Surgery Inflammation Pipeline https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Post-operative Cataract Surgery Inflammation Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Post-operative Cataract Surgery Inflammation market. A detailed picture of the Post-operative Cataract Surgery Inflammation pipeline landscape is provided, which includes the disease overview and Post-operative Cataract Surgery Inflammation treatment guidelines.

Post-operative Cataract Surgery Inflammation Epidemiology https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Post-operative Cataract Surgery Inflammation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Post-operative Cataract Surgery Inflammation epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.